Treatment of travellers' diarrhoea: zaldaride compared with loperamide and placebo.
Eur J Gastroenterol Hepatol
; 7(9): 871-5, 1995 Sep.
Article
em En
| MEDLINE
| ID: mdl-8574720
ABSTRACT
OBJECTIVE:
To compare zaldaride maleate, a calmodulin inhibitor with gastrointestinal antisecretory properties, with loperamide and a placebo in the treatment of travellers' diarrhoea.DESIGN:
Randomized, double-blind, double-dummy study.SETTING:
Study clinic staffed by European residents on Nile cruise ships. PATIENTS Tourists (n = 436) who acquired travellers' diarrhoea during the Nile cruise.INTERVENTIONS:
(1) Zaldaride 20 mg four times daily, (2) zaldaride 2 x 20 mg as initial loading dose followed by three doses of 20 mg on the first day and four doses of 20 mg on the second day, (3) loperamide 2 x 2 mg loading dose following by a flexible dosage of 2 mg after each unformed stool (maximum of 16 mg daily), (4) placebo. MAIN OUTCOMEMEASURES:
Number of unformed stools, rate of improvement of patients with diarrhoea, rate of relief from diarrhoea.RESULTS:
Among the 331 compliant and fully evaluated patients, the zaldaride with loading dose group showed no significant differences in cure rates from the loperamide group. For most parameters, zaldaride without a loading dose and the placebo resulted in significantly lower cure rates.CONCLUSIONS:
A zaldaride regimen including a loading dose was shown to be well tolerated and as effective as loperamide.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Viagem
/
Benzimidazóis
/
Diarreia
/
Loperamida
/
Antidiarreicos
Tipo de estudo:
Clinical_trials
Limite:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
1995
Tipo de documento:
Article